18 results on '"Dufour, Noëlle"'
Search Results
2. Mono- and Biallelic Inactivation of Huntingtin Gene in Patient-Specific Induced Pluripotent Stem Cells Reveal HTT Roles in Striatal Development and Neuronal Functions.
- Author
-
Louessard, Morgane, Cailleret, Michel, Jarrige, Margot, Bigarreau, Julie, Lenoir, Sophie, Dufour, Noëlle, Rey, Maria, Saudou, Frédéric, Deglon, Nicole, and Perrier, Anselme L.
- Subjects
PLURIPOTENT stem cells ,GENE silencing ,HUNTINGTON disease ,CELL physiology ,INDUCED pluripotent stem cells - Abstract
Background: Mutations in the Huntingtin (HTT) gene cause Huntington's disease (HD), a neurodegenerative disorder. As a scaffold protein, HTT is involved in numerous cellular functions, but its normal and pathogenic functions during human forebrain development are poorly understood. Objective: To investigate the developmental component of HD, with a specific emphasis on understanding the functions of wild-type and mutant HTT alleles during forebrain neuron development in individuals carrying HD mutations. Methods: We used CRISPR/Cas9 gene-editing technology to disrupt the ATG region of the HTT gene via non-homologous end joining to produce mono- or biallelic HTT knock-out human induced pluripotent stem cell (iPSC) clones. Results: We showed that the loss of wild-type, mutant, or both HTT isoforms does not affect the pluripotency of iPSCs or their transition into neural cells. However, we observed that HTT loss causes division impairments in forebrain neuro-epithelial cells and alters maturation of striatal projection neurons (SPNs) particularly in the acquisition of DARPP32 expression, a key functional marker of SPNs. Finally, young post-mitotic neurons derived from HTT-/- human iPSCs display cellular dysfunctions observed in adult HD neurons. Conclusions: We described a novel collection of isogenic clones with mono- and biallelic HTT inactivation that complement existing HD-hiPSC isogenic series to explore HTT functions and test therapeutic strategies in particular HTT-lowering drugs. Characterizing neural and neuronal derivatives from human iPSCs of this collection, we show evidence that HTT loss or mutation has impacts on neuro-epithelial and striatal neurons maturation, and on basal DNA damage and BDNF axonal transport in post-mitotic neurons. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Reactive astrocytes promote proteostasis in Huntington's disease through the JAK2-STAT3 pathway.
- Author
-
Abjean, Laurene, Haim, Lucile Ben, Riquelme-Perez, Miriam, Gipchtein, Pauline, Derbois, Céline, Palomares, Marie-Ange, Petit, Fanny, Hérard, Anne-Sophie, Gaillard, Marie-Claude, Guillermier, Martine, Gaudin-Guérif, Mylène, Aurégan, Gwennaëlle, Sagar, Nisrine, Héry, Cameron, Dufour, Noëlle, Robil, Noémie, Kabani, Mehdi, Melki, Ronald, Grange, Pierre De la, and Bemelmans, Alexis P
- Subjects
HUNTINGTON disease ,ASTROCYTES ,STILL'S disease ,MAGNETIC resonance imaging ,VIRAL genes - Abstract
Huntington's disease is a fatal neurodegenerative disease characterized by striatal neurodegeneration, aggregation of mutant Huntingtin and the presence of reactive astrocytes. Astrocytes are important partners for neurons and engage in a specific reactive response in Huntington's disease that involves morphological, molecular and functional changes. How reactive astrocytes contribute to Huntington's disease is still an open question, especially because their reactive state is poorly reproduced in experimental mouse models. Here, we show that the JAK2-STAT3 pathway, a central cascade controlling astrocyte reactive response, is activated in the putamen of Huntington's disease patients. Selective activation of this cascade in astrocytes through viral gene transfer reduces the number and size of mutant Huntingtin aggregates in neurons and improves neuronal defects in two complementary mouse models of Huntington's disease. It also reduces striatal atrophy and increases glutamate levels, two central clinical outcomes measured by non-invasive magnetic resonance imaging. Moreover, astrocyte-specific transcriptomic analysis shows that activation of the JAK2-STAT3 pathway in astrocytes coordinates a transcriptional program that increases their intrinsic proteolytic capacity, through the lysosomal and ubiquitin-proteasome degradation systems. This pathway also enhances their production and exosomal release of the co-chaperone DNAJB1, which contributes to mutant Huntingtin clearance in neurons. Together, our results show that the JAK2-STAT3 pathway controls a beneficial proteostasis response in reactive astrocytes in Huntington's disease, which involves bi-directional signalling with neurons to reduce mutant Huntingtin aggregation, eventually improving disease outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Loss of the thyroid hormone-binding protein Crym renders striatal neurons more vulnerable to mutant huntingtin in Huntingtonʼs disease
- Author
-
Francelle, Laetitia, Galvan, Laurie, Gaillard, Marie-Claude, Guillermier, Martine, Houitte, Diane, Bonvento, Gilles, Petit, Fanny, Jan, Caroline, Dufour, Noëlle, Hantraye, Philippe, Elalouf, Jean-Marc, De Chaldée, Michel, Déglon, Nicole, and Brouillet, Emmanuel
- Published
- 2015
- Full Text
- View/download PDF
5. The striatal long noncoding RNA Abhd11os is neuroprotective against an N-terminal fragment of mutant huntingtin in vivo
- Author
-
Francelle, Laetitia, Galvan, Laurie, Gaillard, Marie-Claude, Petit, Fanny, Bernay, Benoît, Guillermier, Martine, Bonvento, Gilles, Dufour, Noëlle, Elalouf, Jean-Marc, Hantraye, Philippe, Déglon, Nicole, de Chaldée, Michel, and Brouillet, Emmanuel
- Published
- 2015
- Full Text
- View/download PDF
6. Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado–Joseph disease
- Author
-
Nascimento-Ferreira, Isabel, Santos-Ferreira, Tiago, Sousa-Ferreira, Lígia, Auregan, Gwennaëlle, Onofre, Isabel, Alves, Sandro, Dufour, Noëlle, Colomer Gould, Veronica F., Koeppen, Arnulf, Déglon, Nicole, and Pereira de Almeida, Luís
- Published
- 2011
- Full Text
- View/download PDF
7. Silencing ataxin-3 mitigates degeneration in a rat model of Machado–Joseph disease: no role for wild-type ataxin-3?
- Author
-
Alves, Sandro, Nascimento-Ferreira, Isabel, Dufour, Noëlle, Hassig, Raymonde, Auregan, Gwennaëlle, Nóbrega, Clévio, Brouillet, Emmanuel, Hantraye, Philippe, Pedroso de Lima, Maria C., Déglon, Nicole, and de Almeida, Luís Pereira
- Published
- 2010
- Full Text
- View/download PDF
8. Capucin does not modify the toxicity of a mutant Huntingtin fragment in vivo
- Author
-
Galvan, Laurie, Lepejová, Nad'a, Gaillard, Marie-Claude, Malgorn, Carole, Guillermier, Martine, Houitte, Diane, Bonvento, Gilles, Petit, Fanny, Dufour, Noëlle, Héry, Patrick, Gérard, Matthieu, Elalouf, Jean-Marc, Déglon, Nicole, Brouillet, Emmanuel, and de Chaldée, Michel
- Published
- 2012
- Full Text
- View/download PDF
9. Allele-Specific Silencing of Mutant Huntingtin in Rodent Brain and Human Stem Cells.
- Author
-
Drouet, Valérie, Ruiz, Marta, Zala, Diana, Feyeux, Maxime, Auregan, Gwennaëlle, Cambon, Karine, Troquier, Laetitia, Carpentier, Johann, Aubert, Sophie, Merienne, Nicolas, Bourgois-Rocha, Fany, Hassig, Raymonde, Rey, Maria, Dufour, Noëlle, Saudou, Frédéric, Perrier, Anselme L., Hantraye, Philippe, and Déglon, Nicole
- Subjects
ALLELES ,HUNTINGTIN protein ,STEM cells ,LABORATORY rodents ,HUNTINGTON disease ,POLYGLUTAMINE ,RNA interference - Abstract
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder resulting from polyglutamine expansion in the huntingtin (HTT) protein and for which there is no cure. Although suppression of both wild type and mutant HTT expression by RNA interference is a promising therapeutic strategy, a selective silencing of mutant HTT represents the safest approach preserving WT HTT expression and functions. We developed small hairpin RNAs (shRNAs) targeting single nucleotide polymorphisms (SNP) present in the HTT gene to selectively target the disease HTT isoform. Most of these shRNAs silenced, efficiently and selectively, mutant HTT in vitro. Lentiviral-mediated infection with the shRNAs led to selective degradation of mutant HTT mRNA and prevented the apparition of neuropathology in HD rat's striatum expressing mutant HTT containing the various SNPs. In transgenic BACHD mice, the mutant HTT allele was also silenced by this approach, further demonstrating the potential for allele-specific silencing. Finally, the allele-specific silencing of mutant HTT in human embryonic stem cells was accompanied by functional recovery of the vesicular transport of BDNF along microtubules. These findings provide evidence of the therapeutic potential of allele-specific RNA interference for HD. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
10. Sustained effects of nonallele-specific Huntingtin silencing.
- Author
-
Drouet, Valérie, Perrin, Valérie, Hassig, Raymonde, Dufour, Noëlle, Auregan, Gwennaelle, Alves, Sandro, Bonvento, Gilles, Brouillet, Emmanuel, Luthi-Carter, Ruth, Hantraye, Philippe, and Déglon, Nicole
- Abstract
Objective Huntington's disease (HD) is a fatal autosomal dominant neurodegenerative disorder caused by a polyglutamine expansion in the huntingtin (htt) protein. No cure is available to date to alleviate neurodegeneration. Recent studies have demonstrated that RNA interference represents a promising approach for the treatment of autosomal dominant disorders. But whether an allele-specific silencing of mutant htt or a nonallele-specific silencing should be considered has not been addressed. Methods We developed small hairpin RNA targeting mutant or wild-type htt transcripts, or both. Results We confirmed the therapeutic potential of sihtt administered with lentiviral vectors in rodent models of HD and showed that initiation of small interfering RNA treatment after the onset of HD symptoms is still efficacious and reduces the HD-like pathology. We then addressed the question of the impact of nonallele-specific silencing and demonstrated that silencing of endogenous htt to 25 to 35% in vivo is altering several pathways associated with known htt functions but is not inducing overt toxicity or increasing striatal vulnerability up to 9 months after treatment. Interpretation These data indicate that the coincident silencing of the wild-type and mutant htt may be considered as a therapeutic tool for HD. Ann Neurol 2009;65:276-285 [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
11. Normal Aging Modulates the Neurotoxicity of Mutant Huntingtin.
- Author
-
Diguet, Elsa, Petit, Fanny, Escartin, Carole, Cambon, Karine, Bizat, Nicolas, Dufour, Noëlle, Hantraye, Philippe, Déglon, Nicole, and Brouillet, Emmanuel
- Subjects
NEURODEGENERATION ,HUNTINGTON'S chorea treatment ,STEREOTAXIC techniques ,SURGICAL & topographical anatomy ,LABORATORY rats ,HISTOLOGICAL techniques ,CARCINOGENESIS ,GLUTAMINE synthetase ,STEREOENCEPHALOTOMY - Abstract
Aging likely plays a role in neurodegenerative disorders. In Huntington's disease (HD), a disorder caused by an abnormal expansion of a polyglutamine tract in the protein huntingtin (Htt), the role of aging is unclear. For a given tract length, the probability of disease onset increases with age. There are mainly two hypotheses that could explain adult onset in HD: Either mutant Htt progressively produces cumulative defects over time or ''normal'' aging renders neurons more vulnerable to mutant Htt toxicity. In the present study, we directly explored whether aging affected the toxicity of mutant Htt in vivo. We studied the impact of aging on the effects produced by overexpression of an N-terminal fragment of mutant Htt, of wild-type Htt or of a b-Galactosidase (b-Gal) reporter gene in the rat striatum. Stereotaxic injections of lentiviral vectors were performed simultaneously in young (3 week) and old (15 month) rats. Histological evaluation at different time points after infection demonstrated that the expression of mutant Htt led to pathological changes that were more severe in old rats, including an increase in the number of small Htt-containing aggregates in the neuropil, a greater loss of DARPP-32 immunoreactivity and striatal neurons as assessed by unbiased stereological counts. The present results support the hypothesis that ''normal'' aging is involved in HD pathogenesis, and suggest that age-related cellular defects might constitute potential therapeutic targets for HD. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
12. Allele-Specific RNA Silencing of Mutant Ataxin-3 Mediates Neuroprotection in a Rat Model of Machado-Joseph Disease.
- Author
-
Alves, Sandro, Nascimento-Ferreira, Isabel, Auregan, Gwennaëlle, Hassig, Raymonde, Dufour, Noëlle, Brouillet, Emmanuel, de Lima, Maria C. Pedroso, Hantraye, Philippe, de Almeida, Luís Pereira, and Déglon, Nicole
- Subjects
GENETIC research ,RNA ,NEUROSCIENCES ,POLYCYSTIC kidney disease ,GENETIC polymorphisms ,NUCLEOTIDES ,LABORATORY rats ,CENTRAL nervous system ,HUMAN abnormalities - Abstract
Recent studies have demonstrated that RNAi is a promising approach for treating autosomal dominant disorders. However, discrimination between wild-type and mutant transcripts is essential, to preserve wild-type expression and function. A single nucleotide polymorphism (SNP) is present in more than 70% of patients with Machado-Joseph disease (MJD). We investigated whether this SNP could be used to inactivate mutant ataxin-3 selectively. Lentiviral-mediated silencing of mutant human ataxin-3 was demonstrated in vitro and in a rat model of MJD in vivo. The allele-specific silencing of ataxin-3 significantly decreased the severity of the neuropathological abnormalities associated with MJD. These data demonstrate that RNAi has potential for use in MJD treatment and constitute the first proof-of-principle for allele-specific silencing in the central nervous system. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
13. Retinal cell type expression specificity of HIV-1-derived gene transfer vectors upon subretinal injection in the adult rat: influence of pseudotyping and promoter.
- Author
-
Bemelmans, Alexis-Pierre, Bonnel, Sébastien, Houhou, Leïla, Dufour, Noëlle, Nandrot, Emeline, Helmlinger, Dominique, Sarkis, Chamsy, Abitbol, Marc, and Mallet, Jacques
- Abstract
Background Gene therapy, and particularly gene restoration, is currently a great hope for non-curable hereditary retinal degeneration. Clinical applications require a gene transfer vector capable of accurately targeting particular cell types in the retina. To develop such a vector, we compared the expression of a reporter gene after subretinal injections of lentiviral constructs of various pseudotypes and with the transgene expression driven by various promoters. Methods Lentiviral vectors expressing the green fluorescent protein (GFP) under the transcriptional control of cytomegalovirus (CMV), mouse phosphoglycerate kinase (PGK), human elongation factor 1-α (EF1α), or human rhodopsin (RHO) promoters were pseudotyped by vesicular stomatitis virus (VSV) or Mokola virus envelope proteins. These constructs were injected into the subretinal space of adult rdy rats. GFP expression was analyzed in vivo 1 and 4 weeks after injection by fundus examination. The precise location of transgene expression was then determined by immunohistochemistry and in situ hybridization. Results Constructs of both vesicular stomatitis virus and Mokola pseudotypes with ubiquitous promoters led to a strong expression of GFP in vivo. Histological studies confirmed the production of GFP in the retinal pigment epithelium (RPE) in most cases. However, only the combination of the VSV pseudotype with the RHO promoter led to GFP production in photoreceptors, and did so in a sporadic manner. Conclusions Mokola-pseudotyped lentiviral vectors are effective for specific gene transfer to the RPE. Neither VSV- nor Mokola-pseudotyped lentiviral vectors are adequate for efficient gene transfer to photoreceptors of adult rats. Copyright © 2005 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
14. Grafts of Brain-Derived Neurotrophic Factor and Neurotrophin 3-Transduced Primate Schwann Cells Lead to Functional Recovery of the Demyelinated Mouse Spinal Cord.
- Author
-
Girard, Christelle, Bemelmans, Alexis-Pierre, Dufour, Noëlle, Mallet, Jacques, Bachelin, Corinne, Nait-Oumesmar, Brahim, Baron-Van Evercooren, Anne, and Lachapelle, François
- Subjects
MYELIN sheath ,CELL membranes ,LABORATORY mice ,LABORATORY animals ,HIV ,CYTOKINES ,CELL division ,NEUROSCIENCES - Abstract
Experimental studies provided overwhelming proof that transplants of myelin-forming cells achieve efficient remyelination in the CNS. Among cellular candidates, Schwann ceils can be used for autologous transplantation to ensure robust remyelination of lesions and to deliver therapeutic factors in the CNS. In the present study, macaque Schwann cells expressing green fluorescent protein (GFP) were infected with human immunodeficiency virus-derived vectors overexpressing brain-derived neurotrophic factor (BDNF) or Neurotrophin 3 (NT-3), two neurotrophins that also modulate glial cell biology. The ability of transgenic Schwann cells to secrete growth factors was assessed by ELISA and showed 35- and 62-fold increases in BDNF and NT-3, respectively, in transduced macaque Schwann cell supernatants. Conditioned media of BDNF- and NT-3-transduced Schwann cells reduced Schwann cell proliferation and favored their differentiation in vitro. Transgenic cells were grafted in demyelinated spinal cords of adult nude mice. Two behavioral assays showed that NT-3- and BDNF-transduced Schwann cells promoted faster and stronger functional recovery than GFP-transduced Schwann cells. Morphological analysis indicated that functional recovery correlated with enhanced proliferation and differentiation of resident oligodendrocyte progenitors and enhanced oligodendrocyte and Schwann cell differentiation. Moreover, NT-3-transduced Schwann cells provided neuroprotection and reduced astrogliosis. These results underline the potential therapeutic benefit of combining neuroprotection and activation of myelin-forming cells to restore altered functions in demyelinating diseases of the CNS. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
15. The C-Terminal Domain of LRRK2 with the G2019S Substitution Increases Mutant A53T α-Synuclein Toxicity in Dopaminergic Neurons In Vivo.
- Author
-
Cresto, Noémie, Gardier, Camille, Gaillard, Marie-Claude, Gubinelli, Francesco, Roost, Pauline, Molina, Daniela, Josephine, Charlène, Dufour, Noëlle, Auregan, Gwenaëlle, Guillermier, Martine, Bernier, Suéva, Jan, Caroline, Gipchtein, Pauline, Hantraye, Philippe, Chartier-Harlin, Marie-Christine, Bonvento, Gilles, Van Camp, Nadja, Taymans, Jean-Marc, Cambon, Karine, and Liot, Géraldine
- Subjects
DARDARIN ,DOPAMINERGIC neurons ,PARKINSON'S disease ,NEURODEGENERATION ,BEHAVIORAL assessment - Abstract
Alpha-synuclein (α-syn) and leucine-rich repeat kinase 2 (LRRK2) play crucial roles in Parkinson's disease (PD). They may functionally interact to induce the degeneration of dopaminergic (DA) neurons via mechanisms that are not yet fully understood. We previously showed that the C-terminal portion of LRRK2 (ΔLRRK2) with the G2019S mutation (ΔLRRK2
G2019S ) was sufficient to induce neurodegeneration of DA neurons in vivo, suggesting that mutated LRRK2 induces neurotoxicity through mechanisms that are (i) independent of the N-terminal domains and (ii) "cell-autonomous". Here, we explored whether ΔLRRK2G2019S could modify α-syn toxicity through these two mechanisms. We used a co-transduction approach in rats with AAV vectors encoding ΔLRRK2G2019S or its "dead" kinase form, ΔLRRK2DK , and human α-syn with the A53T mutation (AAV-α-synA53T ). Behavioral and histological evaluations were performed at 6- and 15-weeks post-injection. Results showed that neither form of ΔLRRK2 alone induced the degeneration of neurons at these post-injection time points. By contrast, injection of AAV-α-synA53T alone resulted in motor signs and degeneration of DA neurons. Co-injection of AAV-α-synA53T with AAV-ΔLRRK2G2019S induced DA neuron degeneration that was significantly higher than that induced by AAV-α-synA53T alone or with AAV-ΔLRRK2DK . Thus, mutated α-syn neurotoxicity can be enhanced by the C-terminal domain of LRRK2G2019 alone, through cell-autonomous mechanisms. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
16. Lentiviral Delivery of the Human Wild-type Tau Protein Mediates a Slow and Progressive Neurodegenerative Tau Pathology in the Rat Brain.
- Author
-
Caillierez, Raphaëlle, Bégard, Séverine, Lécolle, Katia, Deramecourt, Vincent, Zommer, Nadège, Dujardin, Simon, Loyens, Anne, Dufour, Noëlle, Aurégan, Gwennaëlle, Winderickx, Joris, Hantraye, Philippe, Déglon, Nicole, Buée, Luc, and Colin, Morvane
- Subjects
- *
LENTIVIRUSES , *RETROVIRUSES , *TAU proteins , *TUBULINS , *LABORATORY rats - Abstract
Most models for tauopathy use a mutated form of the Tau gene, MAPT, that is found in frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17) and that leads to rapid neurofibrillary degeneration (NFD). Use of a wild-type (WT) form of human Tau protein to model the aggregation and associated neurodegenerative processes of Tau in the mouse brain has thus far been unsuccessful. In the present study, we generated an original 'sporadic tauopathy-like' model in the rat hippocampus, encoding six Tau isoforms as found in humans, using lentiviral vectors (LVs) for the delivery of a human WT Tau. The overexpression of human WT Tau in pyramidal neurons resulted in NFD, the morphological characteristics and kinetics of which reflected the slow and sporadic neurodegenerative processes observed in sporadic tauopathies, unlike the rapid neurodegenerative processes leading to cell death and ghost tangles triggered by the FTDP-17 mutant Tau P301L. This new model highlights differences in the molecular and cellular mechanisms underlying the pathological processes induced by WT and mutant Tau and suggests that preference should be given to animal models using WT Tau in the quest to understand sporadic tauopathies. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
17. Effect of Chronic Treatment with Riluzole on the Nigrostriatal Dopaminergic System in Weaver Mutant Mice
- Author
-
Douhou, Aıcha, Debeir, Thomas, Murer, Mario Gustavo, Do, Louis, Dufour, Noëlle, Blanchard, Véronique, Moussaoui, Saliha, Bohme, Georg Andrees, Agid, Yves, and Raisman-Vozari, Rita
- Subjects
- *
DOPAMINERGIC neurons , *NEUROPLASTICITY - Abstract
The effects of a chronic treatment with the anti-glutamate and sodium channel modulating neuroprotective agent riluzole on the degeneration of dopamine-containing neurons were studied in the brain of weaver mutant mice. In these animals, as in Parkinson''s disease, dopaminergic neurons of the nigro-striatal pathway undergo spontaneous and progressive cell death. Homozygous weaver mice were orally treated twice a day with either 8 mg/kg riluzole or placebo for 2 months. Quantification of tyrosine-hydroxylase and dopamine-transporter axonal immunostaining in the striatum revealed that riluzole significantly increased the density of striatal dopaminergic nerve terminals. These results suggest that riluzole protects dopaminergic processes in the weaver mice and/or promotes their neuroplasticity. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
18. The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo.
- Author
-
Cresto, Noémie, Gaillard, Marie-Claude, Gardier, Camille, Gubinelli, Francesco, Diguet, Elsa, Bellet, Déborah, Legroux, Laurine, Mitja, Julien, Auregan, Gwenaëlle, Guillermier, Martine, Josephine, Charlène, Jan, Caroline, Dufour, Noëlle, Joliot, Alain, Hantraye, Philippe, Bonvento, Gilles, Déglon, Nicole, Bemelmans, Alexis-Pierre, Cambon, Karine, and Liot, Géraldine
- Subjects
- *
DOPAMINERGIC neurons , *DARDARIN , *MONOAMINE transporters , *PARKINSON'S disease , *SUBSTANTIA nigra , *NEURODEGENERATION , *DOPAMINE analysis , *CELL death - Abstract
The G2019S substitution in the kinase domain of LRRK2 (LRRK2G2019S) is the most prevalent mutation associated with Parkinson's disease (PD). Neurotoxic effects of LRRK2G2019S are thought to result from an increase in its kinase activity as compared to wild type LRRK2. However, it is unclear whether the kinase domain of LRRK2G2019S is sufficient to trigger degeneration or if the full length protein is required. To address this question, we generated constructs corresponding to the C-terminal domain of LRRK2 (ΔLRRK2). A kinase activity that was increased by G2019➔S substitution could be detected in ΔLRRK2. However biochemical experiments suggested it did not bind or phosphorylate the substrate RAB10, in contrast to full length LRRK2. The overexpression of ΔLRRK2G2019S in the rat striatum using lentiviral vectors (LVs) offered a straightforward and simple way to investigate its effects in neurons in vivo. Results from a RT-qPCR array analysis indicated that ΔLRRK2G2019S led to significant mRNA expression changes consistent with a kinase-dependent mechanism. We next asked whether ΔLRRK2 could be sufficient to trigger neurodegeneration in the substantia nigra pars compacta (SNc) in adult rats. Six months after infection of the substantia nigra pars compacta (SNc) with LV-ΔLRRK2WT or LV-ΔLRRK2G2019S, the number of DA neurons was unchanged. To examine whether higher levels of ΔLRRK2G2019S could trigger degeneration we cloned ΔLRRK2 in AAV2/9 construct. As expected, AAV2/9 injected in the SNc led to neuronal expression of ΔLRRK2WT and ΔLRRK2G2019S at much higher levels than those obtained with LVs. Six months after injection, unbiased stereology showed that AAV-ΔLRRK2G2019S produced a significant ~30% loss of neurons positive for tyrosine hydroxylase- and for the vesicular dopamine transporter whereas AAV-ΔLRRK2WT did not. These findings show that overexpression of the C-terminal part of LRRK2 containing the mutant kinase domain is sufficient to trigger degeneration of DA neurons, through cell-autonomous mechanisms, possibly independent of RAB10. • New LVs and AAVs were developed to study the effects of a C-terminal fragment of LRRK2 containing the kinase domain. • ΔLRRK2G2019S produces molecular and cellular effects that are kinase activity-dependent. • In vivo, ΔLRRK2G2019S leads to DA neurodegeneration when using AAV-mediated gene transfer. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.